Implementation of an AI-based MRD Evaluation and Prediction Model for Multiple Myeloma

Abstract

With the application of hematopoietic stem cell transplantation and new drugs, the progression-free survival rate and overall survival rate of multiple myeloma have been greatly improved, but it is still considered as a kind of disease that cannot be completely cured. Many patients have disease recurrence after complete remission, which is rooted in the presence of minimal residual disease MRD in patients. Studies have shown that positive MRD is an independent adverse prognostic factor affecting survival, so MRD detection is an important indicator to judge the prognosis of patients and guide clinical treatment. At present, multipa-rameter flow cytometry (MFC), polymerase chain reaction (PCR), positron emission tomography (positron emission) Several techniques, such as PET/computer tomography (CT), have been used for MRD detection of multiple myeloma. However, there is still no cure for the disease. "IFM2013-04" four clinical studies confirmed for the first time that proteasome inhibitors (PIs) and immunomodulatory drugs, The synergism and importance of the combination of IMiDs in the treatment of MM, the large Phase 3 clinical study SWOG SO777 compared the combination of bortezomib plus lenalidomide and dexamethasone. The efficacy of VRD and D established the status of VRD first-line treatment of MM, and due to the good efficacy of CD38 monoclonal antibody in large clinical studies, combination therapy with VRD has been recommended as the first-line treatment of MM. However, to explore the clinical value and problems of applying artificial intelligence bone marrow cell recognition system Morphogo in the detection of multiple myeloma minimal residual disease (MRD).